{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:01:06Z","timestamp":1785333666240,"version":"3.55.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"15","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The purpose of this manuscript is to provide an up-to-date overview of the emerging pharmacotherapy options for the treatment and management of metabolic dysfunction\u2013associated steatotic liver disease (MASLD) while also highlighting pathophysiology, diagnostic criteria, risk factors, management of comorbidities, and implications for pharmacist practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>MASLD, formerly known as nonalcoholic fatty liver disease (NAFLD), affects approximately 80 million adults in the US and disproportionately impacts individuals with diabetes and obesity. Recent guidance from the AASLD, ADA, and AACE provides a framework for screening, diagnosis, and pharmacological management aimed at reducing fibrosis, hepatic steatosis, and inflammation. Updated recommendations emphasize risk stratification through noninvasive testing, such as the FIB-4 score, followed by noninvasive imaging when clinically indicated. Fibrosis staging informs subsequent treatment decisions, which may include pharmacological agents such as PPAR agonists (pioglitazone), antioxidants (vitamin E), thyroid hormone receptor-\u03b2 agonists (resmetirom), and GLP-1 or GLP-1\/GIP receptor agonists. While pharmacotherapy plays an essential role in management, lifestyle interventions and comprehensive patient education remain fundamental components of care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>As treatment options for MASLD continue to emerge, it is crucial for pharmacists across all practice settings to optimize patient care. Optimization should occur through early recognition and management of comorbidities and disease, as well as by ensuring access to medications. Effective management of MASLD involves collaboration among all members of the healthcare team to enhance patient outcomes and maintain safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxag095","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T12:41:57Z","timestamp":1774356117000},"page":"e538-e548","source":"Crossref","is-referenced-by-count":2,"title":["Metabolic dysfunction\u2013associated steatotic liver disease: Integrating metabolic and hepatic management into pharmacy practice"],"prefix":"10.1093","volume":"83","author":[{"given":"John P","family":"Knorr","sequence":"first","affiliation":[{"name":"Jefferson Einstein Philadelphia Hospital , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Reese","sequence":"additional","affiliation":[{"name":"Saint Joseph\u2019s University Philadelphia College of Pharmacy , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Serbantez","sequence":"additional","affiliation":[{"name":"The University of Texas at Austin College of Pharmacy , Austin, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn P","family":"Lin","sequence":"additional","affiliation":[{"name":"The University of Texas at Austin College of Pharmacy , Austin, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"1","key":"2026072711521794000_zxag095-B1","doi-asserted-by":"publisher","first-page":"e2454707","DOI":"10.1001\/jamanetworkopen.2024.54707","article-title":"Estimated burden of metabolic dysfunction-associated steatotic liver disease in US adults, 2020 to 2050","volume":"8","author":"Le","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026072711521794000_zxag095-B2","author":"Food and Drug Administration"},{"issue":"6","key":"2026072711521794000_zxag095-B3","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"5","key":"2026072711521794000_zxag095-B4","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1097\/HEP.0000000000000860","article-title":"MASH clinical trials and drugs pipeline: an impending tsunami","volume":"82","author":"Noureddin","year":"2025","journal-title":"Hepatology"},{"key":"2026072711521794000_zxag095-B5","author":"Food and Drug Administration"},{"issue":"1","key":"2026072711521794000_zxag095-B6","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"12","key":"2026072711521794000_zxag095-B7","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"issue":"5","key":"2026072711521794000_zxag095-B8","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1097\/HEP.0000000000000670","article-title":"Metabolic dysfunction-associated steatotic liver disease: update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease","volume":"79","author":"Kanwal","year":"2024","journal-title":"Hepatology"},{"issue":"6","key":"2026072711521794000_zxag095-B9","doi-asserted-by":"publisher","first-page":"789","DOI":"10.5604\/16652681.1171749","article-title":"Drug-induced fatty liver disease: an overview of pathogenesis and management","volume":"14","author":"Satapathy","year":"2015","journal-title":"Ann Hepatol"},{"issue":"4","key":"2026072711521794000_zxag095-B10","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.cld.2013.07.012","article-title":"Drug-induced steatohepatitis","volume":"17","author":"Patel","year":"2013","journal-title":"Clin Liver Dis"},{"issue":"7","key":"2026072711521794000_zxag095-B11","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"issue":"12","key":"2026072711521794000_zxag095-B12","doi-asserted-by":"publisher","first-page":"e0324","DOI":"10.1097\/HC9.0000000000000324","article-title":"Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States","volume":"7","author":"Ochoa-Allemant","year":"2023","journal-title":"Hepatol Commun"},{"issue":"3","key":"2026072711521794000_zxag095-B13","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1097\/HEP.0000000000000604","article-title":"National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature","volume":"79","author":"Lee","year":"2024","journal-title":"Hepatology"},{"issue":"7","key":"2026072711521794000_zxag095-B14","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1002\/hep4.1935","article-title":"Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017\u20132018 transient elastography data and application of machine learning","volume":"6","author":"Noureddin","year":"2022","journal-title":"Hepatol Commun"},{"issue":"1","key":"2026072711521794000_zxag095-B15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis","volume":"8","author":"Quek","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"2026072711521794000_zxag095-B16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41572-025-00599-1","article-title":"Metabolic dysfunction-associated steatotic liver disease in adults","volume":"11","author":"Huang","year":"2025","journal-title":"Nat Rev Dis Prim"},{"issue":"10","key":"2026072711521794000_zxag095-B17","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/S2468-1253(24)00193-6","article-title":"Natural history and progression of metabolic dysfunction-associated steatotic liver disease","volume":"9","author":"Hagstr\u00f6m","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"2026072711521794000_zxag095-B18","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.jhep.2022.07.004","article-title":"Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design","volume":"77","author":"Allen","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"2026072711521794000_zxag095-B19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"17","key":"2026072711521794000_zxag095-B20","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/nejmoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"2026072711521794000_zxag095-B21","doi-asserted-by":"publisher","first-page":"e0352","DOI":"10.1097\/HC9.0000000000000352","article-title":"The changing epidemiology of adult liver transplantation in the United States in 2013-2022: the dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease","volume":"8","author":"Younossi","year":"2024","journal-title":"Hepatol Commun"},{"issue":"2S1","key":"2026072711521794000_zxag095-B22","doi-asserted-by":"publisher","first-page":"S193","DOI":"10.1016\/j.ajt.2025.01.022","article-title":"OPTN\/SRTR 2023 annual data report: liver","volume":"25","author":"Kwong","year":"2025","journal-title":"Am J Transplant"},{"issue":"5","key":"2026072711521794000_zxag095-B23","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"issue":"5","key":"2026072711521794000_zxag095-B24","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","article-title":"American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"5","key":"2026072711521794000_zxag095-B25","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"3","key":"2026072711521794000_zxag095-B26","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO)","year":"2024","journal-title":"J Hepatol"},{"issue":"7","key":"2026072711521794000_zxag095-B27","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2337\/dci24-0094","article-title":"Metabolic dysfunction\u2013associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American Diabetes Association","volume":"48","author":"Cusi","year":"2025","journal-title":"Diabetes Care"},{"issue":"2","key":"2026072711521794000_zxag095-B28","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1097\/HEP.0000000000000843","article-title":"AASLD practice guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis","volume":"81","author":"Sterling","year":"2025","journal-title":"Hepatology"},{"issue":"1","key":"2026072711521794000_zxag095-B29","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/HEP.0000000000000845","article-title":"AASLD practice guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis","volume":"81","author":"Sterling","year":"2025","journal-title":"Hepatology"},{"issue":"10","key":"2026072711521794000_zxag095-B30","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1161\/HYP.0000000000000249","article-title":"AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"82","author":"Jones","year":"2025","journal-title":"Hypertension"},{"key":"2026072711521794000_zxag095-B31","volume-title":"Noncirrhotic NASH With Liver Fibrosis: Developing Drugs for Treatment: Guidance for Industry. Draft Guidance","author":"Department of Health and Human Services","year":"2018"},{"issue":"1","key":"2026072711521794000_zxag095-B32","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","article-title":"Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD practice guidance","volume":"81","author":"Chen","year":"2025","journal-title":"Hepatology"},{"issue":"2","key":"2026072711521794000_zxag095-B33","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3390\/biomedicines10020274","article-title":"Pharmacotherapy for non-alcoholic fatty liver disease: emerging targets and drug candidates","volume":"10","author":"Prikhodko","year":"2022","journal-title":"Biomedicines"},{"issue":"6","key":"2026072711521794000_zxag095-B34","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"17","key":"2026072711521794000_zxag095-B35","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction\u2013associated steatohepatitis","volume":"393","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"issue":"10019","key":"2026072711521794000_zxag095-B36","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"2026072711521794000_zxag095-B37","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction\u2013associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"issue":"18","key":"2026072711521794000_zxag095-B38","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Anjal","year":"2010","journal-title":"N Engl J Med"},{"key":"2026072711521794000_zxag095-B39","author":"Rezdiffra"},{"key":"2026072711521794000_zxag095-B40","author":"Rezdiffra (resmetirom)"},{"key":"2026072711521794000_zxag095-B41","author":"Wegovy (semaglutide)"},{"issue":"5","key":"2026072711521794000_zxag095-B42","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"5","key":"2026072711521794000_zxag095-B43","doi-asserted-by":"publisher","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"issue":"3","key":"2026072711521794000_zxag095-B44","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2337\/diacare.25.3.517","article-title":"Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes","volume":"25","author":"Miyazaki","year":"2022","journal-title":"Diabetes Care"},{"key":"2026072711521794000_zxag095-B45","author":"Actos (pioglitazone). Package insert"},{"issue":"7-8","key":"2026072711521794000_zxag095-B46","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.nut.2014.11.018","article-title":"Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials","volume":"31","author":"Sato","year":"2015","journal-title":"Nutrition"},{"issue":"3","key":"2026072711521794000_zxag095-B47","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41401-024-01396-4","article-title":"How improvements in US FDA regulatory process and procedures led to the drug approval for first ever treatment of a common liver disease","volume":"46","author":"Harvey","year":"2025","journal-title":"Acta Pharmacol Sin"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag095\/67522618\/zxag095.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/15\/e538\/67522618\/zxag095.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/15\/e538\/67522618\/zxag095.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:52:24Z","timestamp":1785167544000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/83\/15\/e538\/8541417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":47,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,3,25]]},"published-print":{"date-parts":[[2026,7,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxag095","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,1]]},"published":{"date-parts":[[2026,3,25]]}}}